Calamos Advisors LLC Purchases 90,097 Shares of Amedisys, Inc. (NASDAQ:AMED)

Calamos Advisors LLC grew its stake in shares of Amedisys, Inc. (NASDAQ:AMED - Free Report) by 22.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 487,444 shares of the health services provider's stock after purchasing an additional 90,097 shares during the quarter. Calamos Advisors LLC owned approximately 1.49% of Amedisys worth $44,255,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Blue Trust Inc. boosted its position in Amedisys by 55.1% during the 4th quarter. Blue Trust Inc. now owns 349 shares of the health services provider's stock valued at $34,000 after buying an additional 124 shares during the period. HBW Advisory Services LLC bought a new position in shares of Amedisys during the fourth quarter valued at about $38,000. Versant Capital Management Inc boosted its holdings in shares of Amedisys by 68.5% during the fourth quarter. Versant Capital Management Inc now owns 450 shares of the health services provider's stock worth $41,000 after purchasing an additional 183 shares during the period. KBC Group NV bought a new stake in shares of Amedisys in the third quarter worth about $63,000. Finally, Signaturefd LLC increased its holdings in Amedisys by 20.9% during the 3rd quarter. Signaturefd LLC now owns 1,367 shares of the health services provider's stock valued at $132,000 after purchasing an additional 236 shares during the period. Institutional investors own 94.36% of the company's stock.

Amedisys Trading Down 0.5 %

NASDAQ AMED traded down $0.44 on Thursday, hitting $92.12. The company's stock had a trading volume of 319,386 shares, compared to its average volume of 298,299. The firm has a market cap of $3.02 billion, a P/E ratio of 36.56, a PEG ratio of 1.82 and a beta of 0.73. Amedisys, Inc. has a 52-week low of $82.15 and a 52-week high of $98.95. The company's 50-day simple moving average is $89.49 and its 200 day simple moving average is $93.88. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05.

Amedisys (NASDAQ:AMED - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The health services provider reported $1.00 EPS for the quarter, missing analysts' consensus estimates of $1.19 by ($0.19). The business had revenue of $587.67 million during the quarter, compared to analysts' expectations of $586.75 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The business's revenue was up 5.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.98 EPS. Research analysts predict that Amedisys, Inc. will post 4.4 EPS for the current fiscal year.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.